Select Medical (SEM)
Market Price (12/27/2025): $14.77 | Market Cap: $1.8 BilSector: Health Care | Industry: Health Care Facilities
Select Medical (SEM)
Market Price (12/27/2025): $14.77Market Cap: $1.8 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.4%, Dividend Yield is 2.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.3%, FCF Yield is 9.8% | Weak multi-year price returns2Y Excs Rtn is -30%, 3Y Excs Rtn is -66% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 153% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 45% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6% | |
| Low stock price volatilityVol 12M is 43% | Key risksSEM key risks include [1] a significant debt burden with leverage around 6x net debt/EBITDA that limits financial flexibility and [2] noted margin pressure from regulatory changes in its critical illness recovery segment. | |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Chronic Disease Management. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.4%, Dividend Yield is 2.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.3%, FCF Yield is 9.8% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 45% |
| Low stock price volatilityVol 12M is 43% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Chronic Disease Management. |
| Weak multi-year price returns2Y Excs Rtn is -30%, 3Y Excs Rtn is -66% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 153% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6% |
| Key risksSEM key risks include [1] a significant debt burden with leverage around 6x net debt/EBITDA that limits financial flexibility and [2] noted margin pressure from regulatory changes in its critical illness recovery segment. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
I am unable to provide the requested information. The specified time period of August 31, 2025, to December 27, 2025, is in the future, and I do not have access to future news or market data.
Show moreStock Movement Drivers
Fundamental Drivers
The 17.4% change in SEM stock from 9/26/2025 to 12/26/2025 was primarily driven by a 42.6% change in the company's P/E Multiple.| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 12.58 | 14.77 | 17.40% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5276.90 | 5368.76 | 1.74% |
| Net Income Margin (%) | 2.59% | 2.05% | -20.99% |
| P/E Multiple | 11.34 | 16.18 | 42.63% |
| Shares Outstanding (Mil) | 123.36 | 120.48 | 2.34% |
| Cumulative Contribution | 17.33% |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SEM | 17.4% | |
| Market (SPY) | 4.3% | 34.1% |
| Sector (XLV) | 15.2% | 48.9% |
Fundamental Drivers
The -2.3% change in SEM stock from 6/27/2025 to 12/26/2025 was primarily driven by a -38.5% change in the company's Net Income Margin (%).| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 15.12 | 14.77 | -2.33% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5219.07 | 5368.76 | 2.87% |
| Net Income Margin (%) | 3.33% | 2.05% | -38.48% |
| P/E Multiple | 10.98 | 16.18 | 47.34% |
| Shares Outstanding (Mil) | 126.20 | 120.48 | 4.54% |
| Cumulative Contribution | -2.53% |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SEM | -2.3% | |
| Market (SPY) | 12.6% | 36.0% |
| Sector (XLV) | 17.0% | 29.5% |
Fundamental Drivers
The -22.5% change in SEM stock from 12/26/2024 to 12/26/2025 was primarily driven by a -72.6% change in the company's Net Income Margin (%).| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 19.07 | 14.77 | -22.53% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3695.32 | 5368.76 | 45.29% |
| Net Income Margin (%) | 7.48% | 2.05% | -72.60% |
| P/E Multiple | 8.60 | 16.18 | 88.02% |
| Shares Outstanding (Mil) | 124.71 | 120.48 | 3.40% |
| Cumulative Contribution | -22.62% |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SEM | -22.5% | |
| Market (SPY) | 15.8% | 33.5% |
| Sector (XLV) | 13.3% | 33.5% |
Fundamental Drivers
The 15.2% change in SEM stock from 12/27/2022 to 12/26/2025 was primarily driven by a 87.3% change in the company's P/E Multiple.| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 12.82 | 14.77 | 15.25% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 6311.89 | 5368.76 | -14.94% |
| Net Income Margin (%) | 2.87% | 2.05% | -28.69% |
| P/E Multiple | 8.64 | 16.18 | 87.34% |
| Shares Outstanding (Mil) | 122.19 | 120.48 | 1.41% |
| Cumulative Contribution | 15.22% |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| SEM | 16.0% | |
| Market (SPY) | 48.0% | 35.6% |
| Sector (XLV) | 18.2% | 35.0% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SEM Return | 19% | 7% | -14% | -4% | 48% | -20% | 26% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| SEM Win Rate | 67% | 58% | 42% | 33% | 58% | 33% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| SEM Max Drawdown | -52% | -7% | -26% | -12% | 0% | -37% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | SEM | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -49.7% | -25.4% |
| % Gain to Breakeven | 98.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -60.3% | -33.9% |
| % Gain to Breakeven | 151.7% | 51.3% |
| Time to Breakeven | 293 days | 148 days |
| 2018 Correction | ||
| % Loss | -39.2% | -19.8% |
| % Gain to Breakeven | 64.5% | 24.7% |
| Time to Breakeven | 222 days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Select Medical's stock fell -49.7% during the 2022 Inflation Shock from a high on 6/25/2021. A -49.7% loss requires a 98.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 brief analogies for Select Medical (SEM):
- Like HCA Healthcare, but specializing in rehabilitation hospitals and long-term acute care.
- Like DaVita for specialized medical rehabilitation and long-term recovery.
AI Analysis | Feedback
- Long-Term Acute Care Hospitals: Provide comprehensive medical care for critically ill patients requiring extended hospital stays.
- Inpatient Rehabilitation Hospitals: Offer intensive physical, occupational, and speech therapy for patients recovering from severe injuries or illnesses.
- Outpatient Rehabilitation Clinics: Deliver physical, occupational, and speech therapy services on anaker outpatient basis.
- Occupational Health Centers: Through its Concentra subsidiary, provides workplace injury care, urgent care, physical therapy, and other employer-focused health services.
AI Analysis | Feedback
Select Medical (symbol: SEM) primarily sells its healthcare services to individuals.
The company serves the following categories of customers:
- Critically Ill and Rehabilitation Hospital Patients: Individuals who require highly specialized, intensive medical care or comprehensive rehabilitation following severe illness, injury, or surgery. This includes patients admitted to Select Medical's critical illness recovery hospitals and inpatient rehabilitation facilities.
- Outpatient Rehabilitation Patients: Individuals seeking physical, occupational, or speech therapy services for recovery from injuries, chronic conditions, or post-surgical rehabilitation, delivered in an outpatient clinic setting.
- Occupational Health and Urgent Care Patients: Individuals receiving services primarily through Select Medical's Concentra division, which includes treatment for work-related injuries, preventive health screenings, physical exams, drug testing, and general urgent care needs. While employer relationships often facilitate these services, the ultimate recipient of the healthcare service is the individual employee or patient.
AI Analysis | Feedback
null
AI Analysis | Feedback
Thomas P. Mullin, Chief Executive Officer
Thomas P. Mullin was appointed Chief Executive Officer of Select Medical on September 2, 2025. He joined Select Medical in 2008 and previously served as co-president, overseeing 140 critical illness recovery and inpatient rehabilitation hospitals, and driving the growth of both divisions nationwide. Over his 17 years with the company, Mr. Mullin has held executive leadership roles of increasing responsibility, including executive vice president from 2020-2023, president of specialty hospitals from 2018-2020, and chief operating officer of specialty hospitals from 2016-2018. Earlier in his career at Select Medical, he held various operational positions at the hospital level within the Critical Illness Recovery Hospital Division, including senior vice president of business and market development, and regional vice president.
Michael F. Malatesta, Executive Vice President & Chief Financial Officer
Michael F. Malatesta has served as Executive Vice President and Chief Financial Officer since October 2023. He is a 24-year veteran of Select Medical, having served as senior vice president of finance since November 2013, and holding various senior finance and accounting positions within the Outpatient Rehabilitation Division. Prior to that, he was Vice President of Outpatient Finance from October 2010 to November 2013, Outpatient Controller from 2002 to 2010, and Director of Outpatient Revenue Accounting from 2000 to 2002. Mr. Malatesta began his career at Select Medical in 1999 as an Accounting Manager for NovaCare Rehabilitation. Before joining the company, he held financial roles at Tenet Healthcare, Health Partners Insurance of Philadelphia, and the Graduate Health System. He is a certified public accountant and started his career in public accounting at Deloitte & Touche LLP.
Robert A. Ortenzio, Executive Chairman & Co-Founder
Robert A. Ortenzio co-founded Select Medical in 1996 with his father, Rocco A. Ortenzio, and has served as a director since February 1997. He was appointed Executive Chairman and Co-Founder on January 1, 2014, and previously served as the company's Chief Executive Officer from January 2005 to December 2013, and as President and Chief Executive Officer from September 2001 to January 2005. From February 1997 to September 2001, Mr. Ortenzio served as President and Chief Operating Officer. In 1986, Mr. Ortenzio co-founded Continental Medical Systems, Inc., where he held various capacities including Senior Vice President, Chief Operating Officer, President, and Chief Executive Officer until August 1996, and the company was sold in 1995. Before co-founding Continental Medical Systems, Inc., he was a Vice President of Rehab Hospital Services Corporation, which was acquired by National Medical Enterprises Inc. in 1985. He also co-founded Select Capital Ventures LLC in 2001. Mr. Ortenzio currently serves on the board of directors of Concentra Group Holdings, LLC.
David S. Chernow, Vice Chairman
David S. Chernow has served as Vice Chairman since September 2025. He previously served as Chief Executive Officer from October 2023 to September 2025, and as President and Chief Executive Officer from January 2014 to October 2023. Prior to joining Select Medical's board in 2002, Mr. Chernow was President and Chief Executive Officer of Oncure Medical Corp., a national network of cancer treatment centers. From 2001 to 2007, he was President and Chief Executive Officer of JA Worldwide (formerly Junior Achievement, Inc.). From 1999 to 2001, he was President of the Physician Services Group at US Oncology, Inc. Mr. Chernow co-founded American Oncology Resources in 1992 and served as its Chief Development Officer until its merger with Physician Reliance Network, Inc., which created US Oncology, Inc. in 1999.
John A. Saich, President
John A. Saich began serving as the sole President of Select Medical on September 2, 2025, having previously held the position of co-president since 2023. A 27-year veteran of Select Medical, Mr. Saich most recently served as executive vice president and chief administrative officer from 2018-2023. In this role, he oversaw outpatient rehabilitation and shared services operations. During his tenure, Mr. Saich has guided the company through successful growth and transition, serving in a variety of senior operational and human resources leadership roles.
AI Analysis | Feedback
The key risks to Select Medical's (SEM) business operations include a significant debt burden, the impact of changes in government reimbursement policies and regulations, and intense competition within the healthcare industry.
- Significant Debt Burden: Select Medical carries a substantial amount of debt, with a net debt/EBITDA ratio that has been around 6x. The company reported $3.66 billion in debt and $1.67 billion in leases as of March 2024, with cash and equivalents not reaching $100 million. This high level of leverage could limit financial flexibility, particularly in a high-interest rate environment, and poses a risk if the company struggles to meet its obligations.
- Changes in Government Reimbursement Policies and Regulations: The healthcare sector is heavily regulated, and Select Medical's revenue and profitability are susceptible to changes in government reimbursement policies, particularly from Medicare and Medicaid. There has been noted margin pressure from regulatory changes in the critical illness recovery segment. A failure to maintain Medicare certifications for its long-term acute care hospitals or inpatient rehabilitation facilities could also lead to a decline in revenue and profitability.
- Intense Competition: Select Medical operates in a competitive post-acute care market, facing rivals such as Encompass Health. This competition from large, well-capitalized entities can constrain Select Medical's ability to grow and may lead to a decrease in revenue and overall profitability.
AI Analysis | Feedback
- The accelerating shift towards digital musculoskeletal (MSK) and virtual physical therapy platforms. Companies offering these services directly to employers and payers are gaining traction, potentially diverting patients from Select Medical's extensive network of outpatient rehabilitation clinics for certain conditions.
- Increasing payer and regulatory pressure to transition post-acute care to lower-cost settings. There is an ongoing trend, reinforced by value-based care initiatives, to reduce lengths of stay and encourage discharges to home-based care or less intensive environments, which could impact patient volumes and reimbursement for Select Medical's critical illness recovery hospitals and inpatient rehabilitation facilities.
AI Analysis | Feedback
Select Medical (symbol: SEM) operates in several key healthcare markets within the United States, including critical illness recovery hospitals, inpatient rehabilitation hospitals, and outpatient rehabilitation centers. The addressable markets for Select Medical's main products and services are as follows:- Critical Illness Recovery Hospitals (Long-Term Acute Care - LTAC): The global long-term acute care market was valued at approximately USD 1.23 billion in 2024 and is projected to reach around USD 2.21 billion by 2034, with North America expected to dominate this market.
- Inpatient Rehabilitation Hospitals: The U.S. skilled nursing facility and rehabilitation market was valued at USD 244.43 billion in 2024 and is projected to reach approximately USD 365.31 billion by 2034.
- Outpatient Rehabilitation Centers (Physical and Occupational Therapy Services): The U.S. occupational and physical therapy services market size was valued at USD 59.43 billion in 2024 and is projected to grow to USD 128.17 billion by 2032. Separately, the United States occupational health market was valued at USD 1.187 billion in 2024 and is estimated to reach USD 2.146 billion by 2033.
AI Analysis | Feedback
Select Medical (SEM) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market trends:
- Expansion of Inpatient Rehabilitation Hospitals and Outpatient Clinics: Select Medical is actively pursuing the development of new inpatient rehabilitation hospitals and the expansion of its outpatient network. The company plans to add 395 inpatient rehabilitation beds by the first half of 2027. Recent activities include the acquisition of a 30-bed critical illness recovery hospital and plans to open new facilities, such as a 45-bed hospital in Temple, Texas, and a 32-bed acute rehab unit in Orlando, Florida.
- Strategic Partnerships and Joint Ventures: The company is leveraging strategic partnerships and joint ventures to broaden its market reach and access new patient populations. An example of this strategy is the equity interest acquisition in Banner Rehabilitation, LLC, and plans to open a fourth hospital in partnership with Banner Health in Tucson during 2026.
- Increasing Demand for Post-Acute Care Services: Demographic shifts, particularly the aging U.S. population, are contributing to a growing demand for specialized post-acute care services, including inpatient rehabilitation. The rising prevalence of chronic conditions like strokes, neurological disorders, orthopedic injuries, diabetes, heart disease, and cancer also necessitates comprehensive rehabilitation programs, providing a stable base for Select Medical's long-term growth.
- Expansion of Clinical Programs and Technology Integration: Select Medical is expanding its range of specialized clinical programs to address a broader spectrum of patient needs, including neurological, stroke, and orthopedic rehabilitation. Additionally, the company is investing in technology, such as telehealth, remote patient monitoring, and data analytics, to enhance patient care and improve operational efficiency.
AI Analysis | Feedback
Capital Allocation Decisions of Select Medical (SEM) Over the Last 3-5 Years
Share Repurchases
- Select Medical has an authorized common stock repurchase program of up to $1.0 billion, which is set to remain in effect until December 31, 2025, unless extended or terminated earlier by the Board of Directors.
- From the program's inception through March 31, 2025, the company repurchased approximately 48.9 million shares at a cost of about $611.7 million, averaging $12.51 per share.
- During the first quarter ended March 31, 2025, Select Medical repurchased 649,804 shares for approximately $11.4 million.
Outbound Investments
- Select Medical has engaged in acquisitions, including one in 2023 and another in 2021.
- In April 2023, Select Medical acquired Vibra Hospital of Richmond, a long-term acute care hospital, which now operates as Select Specialty Hospital – Richmond.
- The company also pursues joint ventures, such as the one in March 2023 with Lutheran Health Network of Indiana to expand critical illness recovery care, and plans to construct a specialty hospital in Florida.
Capital Expenditures
- Expected capital expenditures for 2024 are projected to be in the range of $225 million to $275 million.
- For 2025, capital expenditures are narrowed to an expected range of $180 million to $200 million.
- These expenditures are primarily focused on strategic investments like the development of a new 63-bed inpatient rehabilitation hospital in Missouri, and additional expansions in Florida and Ohio, accelerating inpatient rehab growth.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SEM. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Select Medical
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Critical Illness Recovery Hospital | 2,300 | 2,234 | 2,247 | 2,077 | 1,837 |
| Outpatient Rehabilitation | 1,189 | 1,125 | 1,084 | 920 | 1,046 |
| Rehabilitation Hospital | 980 | 917 | 849 | 735 | 671 |
| Other | 358 | 333 | 292 | 298 | 272 |
| Concentra | 1,724 | 1,732 | 1,501 | 1,629 | |
| Total | 4,826 | 6,334 | 6,205 | 5,532 | 5,454 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Critical Illness Recovery Hospital | 2,497 | 2,485 | 2,304 | 2,214 | 2,100 |
| Non-current assets of discontinued operations | 2,039 | ||||
| Outpatient Rehabilitation | 1,380 | 1,371 | 1,348 | 1,302 | 1,289 |
| Rehabilitation Hospital | 1,234 | 1,201 | 1,194 | 1,149 | 1,127 |
| Current assets of discontinued operations | 291 | ||||
| Other | 248 | 327 | 238 | 590 | 452 |
| Concentra | 2,282 | 2,275 | 2,401 | 2,372 | |
| Total | 7,690 | 7,665 | 7,360 | 7,655 | 7,340 |
Price Behavior
| Market Price | $14.77 | |
| Market Cap ($ Bil) | 1.8 | |
| First Trading Date | 09/25/2009 | |
| Distance from 52W High | -26.3% | |
| 50 Days | 200 Days | |
| DMA Price | $14.25 | $14.39 |
| DMA Trend | down | up |
| Distance from DMA | 3.6% | 2.7% |
| 3M | 1YR | |
| Volatility | 38.0% | 43.4% |
| Downside Capture | 80.32 | 95.26 |
| Upside Capture | 141.28 | 56.08 |
| Correlation (SPY) | 34.8% | 33.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.28 | 1.07 | 1.07 | 1.37 | 0.77 | 0.93 |
| Up Beta | 3.12 | 1.61 | 2.09 | 1.50 | 0.70 | 0.79 |
| Down Beta | -0.92 | 0.49 | 0.42 | 1.79 | 0.81 | 0.86 |
| Up Capture | 188% | 190% | 146% | 92% | 43% | 94% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 12 | 26 | 37 | 71 | 127 | 394 |
| Down Capture | 70% | 68% | 78% | 132% | 98% | 103% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 8 | 16 | 26 | 54 | 120 | 349 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of SEM With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| SEM | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -21.2% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.3% |
| Annualized Volatility | 43.2% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.42 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 33.5% | 33.4% | -0.3% | 7.0% | 31.9% | 10.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of SEM With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| SEM | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 1.6% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 39.1% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.15 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 39.5% | 45.5% | 5.8% | 10.4% | 42.5% | 20.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of SEM With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| SEM | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 9.0% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 43.4% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.35 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 45.7% | 52.3% | 1.0% | 20.6% | 50.1% | 15.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.